Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals (CRVS) will host a conference call and webcast on November 3, 2022, at 4:30 pm ET to report its third-quarter 2022 financial results and provide a business update. Interested participants can join the call by dialing specific numbers, and a replay will be available on the company's website for 90 days. Corvus focuses on developing innovative therapies, with its lead candidate CPI-818 undergoing clinical trials for T-cell lymphomas. Other programs include CPI-444 and CPI-006, targeting critical pathways in cancer treatment.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced the launch of a Phase 1b/2 clinical trial for ciforadenant, aimed at treating metastatic renal cell cancer (RCC). The trial, conducted with the Kidney Cancer Research Consortium, will enroll up to 60 patients, evaluating ciforadenant combined with ipilimumab and nivolumab. The primary endpoints focus on safety and anti-tumor activity, with preliminary results expected early in the trial. The company highlights previous positive data on ciforadenant's efficacy, providing a strong rationale for this investigation.
Corvus Pharmaceuticals announced the approval of an IND application to initiate a Phase 1/1b clinical trial for mupadolimab in China, in partnership with Angel Pharmaceuticals. Mupadolimab targets CD73 to activate immune responses in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell cancers (HNSCC). The trial aims to evaluate the drug’s safety, pharmacokinetics, and efficacy, with plans for a subsequent randomized Phase 2 trial in combination with pembrolizumab and chemotherapy.
Corvus Pharmaceuticals (Nasdaq: CRVS) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Richard A. Miller will present a pre-recorded corporate overview, available on-demand starting September 12 at 7:00 am ET. The presentation will be accessible for 90 days on the Corvus investor relations webpage. Corvus focuses on developing innovative treatments for T-cell lymphomas, notably its lead candidate CPI-818 and other programs such as ciforadenant and mupadolimab.
Corvus Pharmaceuticals (CRVS) provided a business update and financial results for Q2 2022. The company is prioritizing CPI-818 for T cell lymphomas and related autoimmune diseases, showing promising early clinical data. Additionally, it plans a Phase 2 trial for ciforadenant in metastatic renal cell cancer with the Kidney Cancer Clinical Trials Consortium in Q3 2022. However, development of mupadolimab for lung cancer is paused to focus resources. As of June 30, 2022, cash reserves amounted to $56.7 million, projected to fund operations into early 2024.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced a conference call and webcast scheduled for August 8, 2022, at 4:30 PM ET to report second quarter 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on Corvus' investor relations page, with a replay available for 90 days. Corvus focuses on developing novel therapies, including mupadolimab (CPI-006) and CPI-818, for the treatment of various cancers.
Corvus Pharmaceuticals (Nasdaq: CRVS) has appointed Dr. James Rosenbaum as Senior Vice President of Research to lead the development of CPI-818, an ITK inhibitor aimed at treating immune disorders and T cell lymphomas. CPI-818 is currently in a Phase 1/1b clinical trial with promising interim results that may support future Phase 2 trials. Dr. Rosenbaum brings extensive experience in immunology and autoimmune diseases, enhancing the company's research capabilities in clinical and preclinical settings.
Corvus Pharmaceuticals (Nasdaq: CRVS) hosted an R&D Symposium showcasing interim data from the Phase 1/1b study of CPI-818 in patients with relapsed T cell lymphomas. The trial identified a 200 mg optimal dose, with notable patient responses, including a complete remission lasting 19 months. Key findings indicate CPI-818's potential in enhancing anti-tumor immunity without directly killing cancer cells. The company plans to expand its study, with future data releases anticipated, and aims to initiate a global Phase 2 trial if trends continue.
Corvus Pharmaceuticals (CRVS) reported its Q1 2022 financial results, revealing cash reserves of $62.9 million, down from $69.5 million at the end of 2021. The net loss narrowed to $8.3 million compared to $11.6 million in Q1 2021. The company is advancing three clinical candidates, including mupadolimab for non-small cell lung cancer and ciforadenant for renal cell cancer, with trials set to start later in the year. Corvus will host an R&D Symposium on May 10, 2022, to discuss these clinical efforts.
Corvus Pharmaceuticals will host an R&D Symposium on May 10, 2022, in New York City, from 9:00 AM to 11:30 AM ET. The event aims to update on three clinical programs: anti-CD73 (mupadolimab), adenosine 2A receptor antagonist (ciforadenant), and ITK inhibitor (CPI-818) in T cell lymphomas. The symposium will feature insights from Corvus President Richard A. Miller, M.D., along with expert speakers from Stanford University and Angel Pharmaceuticals. The event will be webcast live and available for replay for 90 days.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
